Clinical trials: Myeloma
Multiple Myeloma
A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D Chimeric antigen receptor (CAR) T-cells in patients with relapsed or refractory multiple myeloma who received…
- Trial name
- NCT05998928
- Testing
- Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Multiple Myeloma
A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b
The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma
- Trial name
- NCT00423644
- Testing
- Darinaparson
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- Alaunos Therapeutics
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Neoplasm
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
This phase I/Ib trial studies the side effects and best dose of ipilimumab or nivolumab in treating patients with cancers of the blood and blood-forming tissues (hematologic cancers) that have returned after a period of…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT01822509
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 13 sites in United States
- Volunteers
- 71 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Plasma Cell Myeloma
Chaplain-Delivered Compassion Meditation to Improve Quality of Life in Patients Receiving a Stem Cell Transplant
This clinical trial tests whether chaplain-delivered compassion centered spiritual health (CCSH) works to improve quality of life in patients receiving a stem cell transplant.
- Trial name
- NCT05274763
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Spiritual Therapy
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Emory University
Smoldering Plasma Cell Myeloma
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
This pilot early phase I trial studies pembrolizumab in treating patients with slow growing (smoldering) multiple myeloma with intermediate or high-risk of spreading.
- Trial name
- NCT02603887
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
This is a prospective, 2-arm (with an additional exploratory arm), open-label, multicenter study looking at the response rate of patients receiving selinexor (KPT-330), in combination with carfilzomib, daratumumab or…
- Trial name
- NCT04661137
- Testing
- Selinexor 60 MG, Selinexor 80 MG, Selinexor 100 MG
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- Hackensack Meridian Health
Relapsed or Refractory Multiple Myeloma
Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy
This is a prospective long-term follow-up (LTFU) study to evaluate the long-term safety and survival benefit for patients who received at least one of CARsgen's GM T cell product in a clinical trial or as a commercially available…
- Trial name
- NCT06825845
- Testing
- Zevorcabtagene Autoleucel
- Volunteers
- 1,500 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Identification of Occupational Exposures in Acute Hematologic Malignancy
Lymphoid hemopathies are a group of malignant haematological disorders characterized by clonal proliferation of cells of the lymphoid line.
- Conditions
- Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma
- Trial name
- RHELYPRO (NCT03316209)
- Where
- 7 sites in France
- Volunteers
- 205 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Relapsed/ Refractory Multiple Myeloma
A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
This is a single center, single arm, open-label, dose-escalation clinical study to observe the safety, tolerability, preliminary efficacy, pharmacokinetics, pharmacodynamics of ESO-T01 injection for treating patients with…
- Trial name
- NCT06791681
- Testing
- ESO-T01
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chunrui Li
Multiple Myeloma
Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study)
The purpose of this study is to characterize the multiple myeloma (MM) participants with symptomatic relapse and/or refractory disease in Spain.
- Trial name
- NCT03188536
- Testing
- No Intervention
- Where
- 30 sites in Spain
- Volunteers
- 282 people
- Sponsor
- Takeda
Hematological Malignancies, Leukemia
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
This research study uses a drug called cyclophosphamide to decrease the incidence of GVHD in matched sibling hematopoietic stem cell transplant. In doing so, the goal of the study is to increase overall survival.
- Conditions
- Hematological Malignancies, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT01315132
- Testing
- Matched Sibling Allogeneic Transplantation
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Relapsed and Refractory Multiple Myeloma (RRMM)
SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
This is a Phase I, single-center, single-arm, open-label clinical study to evaluate the safety, tolerability, and preliminary efficacy of SL4903 autologous T-cell injection (CAR-T cell therapy) in adult patients with relapsed or…
- Trial name
- SL4903 (NCT07234721)
- Testing
- SL4903 Autologous T-Cell Injection
- Volunteers
- 9 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Leukemia, Chronic Leukemia
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
The purpose of this study is to determine the safety and maximum tolerated dose, pharmacokinetics, and anti-neoplastic response of AVN-944 in patients with advanced hematologic malignancies.
- Conditions
- Acute Leukemia, Chronic Leukemia, Multiple Myeloma, Hodgkin's Lymphoma
- Trial name
- NCT00273936
- Testing
- AVN-944 capsules for oral administration
- Where
- 5 sites in United States
- Volunteers
- 72 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
This phase II trial is studying how well umbilical cord blood transplant from a donor works in treating patients with hematological cancer.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Myelogenous Leukemia
- Trial name
- NCT00723099
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- 6 sites in United States
- Volunteers
- 73 people
- Sponsor
- Fred Hutchinson Cancer Center
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)
Multi-center, open-label, single-dose, dose-escalating Phase I/II study of GS 9219 in adult patients with relapsed or refractory CLL, NHL or MM. Patients will be enrolled into the study in sequential dose cohorts.
- Conditions
- Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma
- Trial name
- NCT00499239
- Testing
- GS-9219
- Where
- 20 sites in United States, Czechia and 1 more
- Volunteers
- 32 people
- Sponsor
- Gilead Sciences
Multiple Myeloma
Connect® MM- The Multiple Myeloma Disease Registry
The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the…
- Trial name
- NCT01081028
- Testing
- First-line therapy, Second-line Multiple Myeloma treatments
- Where
- 253 sites in United States, Puerto Rico
- Volunteers
- 3,011 people
- Sponsor
- Celgene
Multiple Myeloma
MYeloma Resistance And Clonal Evolution
Multiple Myeloma (MM) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis.
- Trial name
- MYRACLE (NCT03807128)
- Testing
- Prélèvement sanguin (2*4mL) ou médullaire (2mL), Data collection through questionnaires
- Where
- 2 sites in France
- Volunteers
- 1,400 people
- Sponsor
- Nantes University Hospital
Multiple Myeloma
Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Primary Objectives: To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) To assess the safety and tolerability (including local injection site tolerability) of…
- Trial name
- NCT04045795
- Testing
- isatuximab SAR650984 IV, pomalidomide, dexamethasone
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 56 people
- Sponsor
- Sanofi
Multiple Myeloma
Geriatric Assessments in Senior Adults With Multiple Myeloma
This study will evaluate the prevalence of geriatric syndromes in older adults with multiple myeloma, examine relationships between baseline geriatrics syndromes and initial treatment selection, and examine risk of functional…
- Trial name
- NCT01746030
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma
Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients
An unrandomized phase 2 study of selinexor in combination with lenalidomide/ bortezomib and dexamethasone to newly diagnosed, transplant in-eligible symptomatic multiple myeloma patients in a multicenter international set-up…
- Trial name
- SABLe (NCT04717700)
- Testing
- Selinexor 20 MG Oral Tablet, Bortezomib Injection, Lenalidomide capsule
- Where
- 11 sites in Denmark, Estonia and 1 more
- Volunteers
- 50 people
- Sponsor
- Ida Bruun Kristensen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.